DK1007020T3 - 9-cis-retinoidsyre til cellemedierede immunsygdomme - Google Patents

9-cis-retinoidsyre til cellemedierede immunsygdomme

Info

Publication number
DK1007020T3
DK1007020T3 DK98947437T DK98947437T DK1007020T3 DK 1007020 T3 DK1007020 T3 DK 1007020T3 DK 98947437 T DK98947437 T DK 98947437T DK 98947437 T DK98947437 T DK 98947437T DK 1007020 T3 DK1007020 T3 DK 1007020T3
Authority
DK
Denmark
Prior art keywords
cis
pharmaceutically acceptable
retinoic acid
mediated immune
cell
Prior art date
Application number
DK98947437T
Other languages
Danish (da)
English (en)
Inventor
Werner Bollag
Fritz Ott
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Application granted granted Critical
Publication of DK1007020T3 publication Critical patent/DK1007020T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK98947437T 1997-08-23 1998-08-18 9-cis-retinoidsyre til cellemedierede immunsygdomme DK1007020T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97114651A EP0908179A1 (en) 1997-08-23 1997-08-23 Treatment of cell-mediated immune diseases

Publications (1)

Publication Number Publication Date
DK1007020T3 true DK1007020T3 (da) 2004-06-07

Family

ID=8227266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98947437T DK1007020T3 (da) 1997-08-23 1998-08-18 9-cis-retinoidsyre til cellemedierede immunsygdomme

Country Status (18)

Country Link
US (2) US6589989B1 (tr)
EP (2) EP0908179A1 (tr)
JP (1) JP3522220B2 (tr)
KR (1) KR100596260B1 (tr)
CN (1) CN1136845C (tr)
AT (1) ATE259224T1 (tr)
AU (1) AU739440B2 (tr)
BR (1) BRPI9811989B8 (tr)
CA (1) CA2301907C (tr)
DE (1) DE69821624T2 (tr)
DK (1) DK1007020T3 (tr)
ES (1) ES2214729T3 (tr)
NO (1) NO327141B1 (tr)
NZ (1) NZ502812A (tr)
PT (1) PT1007020E (tr)
RU (1) RU2238083C2 (tr)
TR (1) TR200000488T2 (tr)
WO (1) WO1999009969A1 (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
FR2834216B1 (fr) * 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
TW579640B (en) * 2002-10-23 2004-03-11 Veutron Corp Light gathering device of scanner
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
CA2520018C (en) 2003-04-11 2011-01-04 F. Hoffmann-La Roche Ag Process for the production of 9-cis retinoic acid
US7122751B1 (en) * 2004-01-16 2006-10-17 Cobalt Flux Switch apparatus
WO2005070413A1 (ja) * 2004-01-23 2005-08-04 Japan Science And Technology Agency レチノイン酸を含有する糖尿病治療薬
AU2015207903B2 (en) * 2004-06-18 2017-08-17 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2006002097A2 (en) 2004-06-18 2006-01-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2012216808B2 (en) * 2004-06-18 2015-04-30 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
EP2286807A3 (en) * 2005-09-09 2012-08-29 Kemphys Ltd. Medicament for preventive and/or therapeutic treatment of adhesion of bowel
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US8580278B2 (en) * 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
US20120178806A1 (en) 2009-09-15 2012-07-12 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
KR20180043846A (ko) 2010-04-19 2018-04-30 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN102247348A (zh) * 2011-05-23 2011-11-23 天津拓飞生物科技有限公司 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
CA2875798A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US9221854B2 (en) 2012-08-17 2015-12-29 Basf Se Isomerization of olefinic compounds
JP6461792B2 (ja) 2012-08-17 2019-01-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ オレフィン化合物の異性化
US20150202172A1 (en) * 2014-01-22 2015-07-23 Glaxo Group Limited Novel method of use
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN113499335B (zh) * 2021-07-13 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种靶向自噬融合治疗神经退行性疾病的药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5932622A (en) * 1991-12-18 1999-08-03 The Salk Institute For Biological Studies Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid
KR100274101B1 (ko) 1992-01-22 2000-12-15 프리돌린 클라우스너, 롤란드 비. 보레르 9-시스 레틴산을 함유하는 약제학적 조성물
US5750570A (en) * 1992-03-31 1998-05-12 The Regents Of The University Of Michigan Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
TW272187B (tr) * 1992-05-20 1996-03-11 Hoffmann La Roche
WO1994022818A1 (en) * 1993-04-05 1994-10-13 Pfizer Inc. Method for the preparation of 9-cis retinoic acid
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
DE4415204A1 (de) * 1994-04-30 1995-11-02 Carl Heinrich Dr Weischer Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5721103A (en) * 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders

Also Published As

Publication number Publication date
NO327141B1 (no) 2009-05-04
AU9435698A (en) 1999-03-16
EP1007020B1 (en) 2004-02-11
BR9811989A (pt) 2000-09-05
DE69821624D1 (de) 2004-03-18
CA2301907A1 (en) 1999-03-04
CN1268886A (zh) 2000-10-04
RU2238083C2 (ru) 2004-10-20
NO20000870D0 (no) 2000-02-22
ES2214729T3 (es) 2004-09-16
JP3522220B2 (ja) 2004-04-26
TR200000488T2 (tr) 2000-07-21
EP0908179A1 (en) 1999-04-14
WO1999009969A1 (en) 1999-03-04
ATE259224T1 (de) 2004-02-15
JP2003526595A (ja) 2003-09-09
CA2301907C (en) 2009-02-10
BRPI9811989B8 (pt) 2021-05-25
CN1136845C (zh) 2004-02-04
DE69821624T2 (de) 2004-09-23
KR20010023186A (ko) 2001-03-26
NZ502812A (en) 2002-05-31
NO20000870L (no) 2000-02-22
AU739440B2 (en) 2001-10-11
US20040039056A1 (en) 2004-02-26
EP1007020A1 (en) 2000-06-14
KR100596260B1 (ko) 2006-07-03
PT1007020E (pt) 2004-05-31
BRPI9811989B1 (pt) 2015-12-15
US6589989B1 (en) 2003-07-08

Similar Documents

Publication Publication Date Title
DK1007020T3 (da) 9-cis-retinoidsyre til cellemedierede immunsygdomme
Windhorst et al. General clinical toxicology of oral retinoids
IE871981L (en) Programmed release formulation.
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
DE69206345D1 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2307879A1 (en) Treatment of t-helper cell type 2 mediated immune diseases
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
EP0414772A4 (en) Method for treating acne
KR910005858A (ko) 지방산 요법
JPH04243825A (ja) 色素沈着症治療剤
EP0265042A3 (en) Ophthalmic compositions comprising a tetraalkyl pyrazine
DE69227072D1 (de) Pharmazeutische Zusammensetzung, die als Hilfsmittelbehandlung von Seborrhoid-Dermatitis, auch bei HIV-Patienten, verwendbar ist
Thune Treatment of Palmoplantar Pustulosis with Tigason®
WO2000026185A3 (en) Omeprazole solution and method of using same
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
CA2373611C (en) Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
US4218445A (en) N,N'Dibenzylethylenediamine-diacetylsalicylate, a novel chemotherapeutic agent for pain relief by external application
CN1260982A (zh) 入地金牛外用止痛中药
UA36078A (uk) Спосіб комплексного лікування хронічного катарального гінгівіту у дітей, хворих на цукровий діабет